Control Bionics Ltd
CBL
Company Profile
Business description
Control Bionics Ltd is engaged in the healthcare device business. It is involved in developing, commercializing, and selling assistive communications technology systems within the disability sector. Its core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. Geographically, it derives a majority of revenue from North America and has its presence in Australia as well.
Contact
11-13 Pearson Street
Level 4
CremorneVIC3121
AUST: +61 398973576
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
What Q4 US earnings did and didn’t tell us about AI and the outlook for tech shares
Tech saw solid earnings, but there are more questions around which companies will benefit from AI, and which will be hurt.
stocks
Top stocks of the year: Which opportunities remain in 2026?
A deep dive into the most traded stocks by Aussies in 2025 - and what this signals for the year ahead.
stocks
What did Morningstar subscribers buy and sell during February?
How the most traded shares stack up against our analysts views.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,085.10 | 36.30 | 0.40% |
| CAC 40 | 8,045.80 | 121.93 | -1.49% |
| DAX 40 | 23,815.75 | 389.61 | -1.61% |
| Dow JONES (US) | 47,954.74 | 784.67 | -1.61% |
| FTSE 100 | 10,413.94 | 153.71 | -1.45% |
| HKSE | 25,719.35 | 398.01 | 1.57% |
| NASDAQ | 22,748.99 | 58.50 | -0.26% |
| Nikkei 225 | 55,620.84 | 342.78 | 0.62% |
| NZX 50 Index | 13,519.35 | 98.54 | -0.72% |
| S&P 500 | 6,830.71 | 38.79 | -0.56% |
| S&P/ASX 200 | 8,851.00 | 25.80 | 0.29% |
| SSE Composite Index | 4,124.19 | 15.63 | 0.38% |